We got some news to talk about today and it just so happens to be some good news and some bad news. In both cases, the news is specific enough.
The sector did get some momentum with the news yesterday but it still feels like a grind that is in a holding pattern, although clearly not like the broader market.
It still looks to me that the sector is acting less like a sector and more like an aggregation of individual stocks. That is always true (it is not a.
They say that the market never bottoms on a Friday and I wonder if the same is true of topping? The sector has clearly had a strong near term move.
Another slow news day with a more of the same market. What looked like a developing trend of strong small cap performance has morphed back into the run of the.
The following stocks had recent and notable activity in their options: $INFI (8/6): 3,822 SEP 10.0 strike Puts were sold (stock at $9.98) for 0.45 or total proceeds of $171,990..
(with Jason Chew) Lysosomal Disease Network WORLD Symposium meeting The Lysosomal Disease Network (LDN) WORLD Symposium provides an interdisciplinary forum to explore and discuss specific areas of research and clinical.
With the JP Morgan Healthcare Conference wrapped up, I wanted to highlight some notes from the Wednesday session. I tried to keep them as concise as possible. We will say.
With Phase 3 data expected from Amicus Therapeutics (NASDAQ : FOLD), we wanted to take the time to do a thorough analysis of the trial and what to expect. Jason.
Amicus Therapeutics, Inc. (NASDAQ: FOLD) With FOLD on the move again, we wanted to look at how the stock is performing from a technical perspective , especially after Patrick’s report.
Amicus Therapeutics released updated data Thursday for its chaperone molecule Amigal (migalastat) for Fabry disease at the American Society of Human Genetics (ASHG) Annual Meeting. Results looked good, continuing to.
Amicus Therapeutics is expected to unveil results from its Phase III registration trial for migalastat (Amigal) as monotherapy for the treatment of Fabry disease in the third quarter of this.
With the close of the first half of 2012 upon us, we wanted to highlight some of those expected to report data or regulatory decisions before the end of June..
Investors in Amicus Therapeutics (NASDAQ: FOLD) are anxiously awaiting data from several ongoing trials in rare-diseases. We initiated coverage on Amicus back in January[link]. We are waiting data from the.
FOLD: Initiating Coverage Overview: Now here is an interesting story. Amicus Therapeutics was founded in 2002 by serial entrepreneur and CEO John Crowley. He had previously founded Novozyme seeking a.